Adjuvant systemic therapy for primary breast cancer.
Chemotherapy and tamoxifen will continue to play an important role in the treatment of patients with primary breast cancer. Future clinical trials will clarify the role of HDCT for patients at high risk. Molecular markers of response may assist in drug selection in the adjuvant setting. Development of novel therapeutic agents continues based on an expanded biologic understanding of tumor development and progression.
Esteva
F J
FJ
Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA. festeva@notes.mdacc.tmc.edu
Hortobagyi
G N
GN
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000209:etiology; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D015195:Drug Design; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013629:Tamoxifen / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D013629:Tamoxifen